Polatuzumab (with rituximab and bendamustine)

Red

Brand Name(s):

Indication:Relapsed or refractory diffuse large B cell lymphoma in adults

Rationale:1,2,8

Considered:Nov-20

Review Date:Nov-25

Comments:
NICE recommends use of polatuzumab vedotin with rituximab and bendamustine as an option for treating relapsed or refractory diffuse large B cell lymphoma in adults who cannot have a haematopoietic stem cell transplant.

NICE TA649